Conclusions: Peak SUV, main lesion SUVmax, serum MMP-2, and the tumor glycolytic activity are good predictors of PFS of patients with pancreatic adenocarcinoma. The gene discussed is MMP2; the disease is pancreatic adenocarcinoma.